한글목차

세계 비소세포폐암(NSCLC) 시장은 2025년 286억 1,000만 달러, 2032년에는 543억 8,000만 달러에 달할 것으로 예측되며, 2025-2032년간 연평균 9.6%의 성장률을 보일 것으로 예상됩니다.

그림. 2025년 지역별 비소세포폐암(NSCLC) 시장 점유율(%)

비소세포폐암(NSCLC)은 전체 폐암의 약 85%를 차지하는 가장 유병률이 높은 폐암입니다. 전 세계 암 관련 사망의 주요 원인 중 하나입니다. 세계 비소세포폐암(NSCLC) 시장의 성장은 흡연 습관 및 환경오염의 확산, 첨단 치료법 연구개발 활동의 활성화, 표적치료 및 맞춤치료에 대한 수요 증가 등의 요인에 의해 이루어지고 있습니다. 그러나 높은 치료비용이 시장 성장의 걸림돌로 작용하고 있습니다.

시장 역학

세계 비소세포폐암(NSCLC) 시장 성장의 원동력은 선진국과 신흥국 모두에서 흡연율 증가, 환경오염 수준 증가, 고령화 등이며, WHO에 따르면 전 세계적으로 매년 약 180만 건의 새로운 폐암 사례가 보고되고 있으며, 그 중 대부분은 비소세포폐암입니다. 표적 치료와 암 치료법의 발전은 시장 관계자들에게 기회를 제공합니다. 그러나 표적 치료와 관련된 높은 비용과 저소득 국가에서의 인식 부족이 시장 성장의 걸림돌로 작용하고 있습니다. 또한, 검사 중 약물이 실패할 위험도 연구개발 활동에 악영향을 미치고 있습니다.

본 조사의 주요 특징

• 세계의 비소세포폐암(비소세포폐암) 시장을 상세하게 분석했으며, 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 연평균 성장률(CAGR)에 대해 조사 분석하여 전해드립니다.
• 또한, 다양한 부문에 걸친 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
• 또한 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
• 이 보고서는 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 성과, 전략 등의 매개 변수를 기반으로 세계 비소세포폐암(NSCLC) 시장의 주요 기업 프로파일을 제공합니다.
• 이 보고서의 통찰력을 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형화, 시장 확대, 마케팅 전술에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 보입니다.
• 세계 비소세포폐암(NSCLC) 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 산업의 다양한 이해관계자를 대상으로 합니다.
• 이해관계자들은 세계 비소세포폐암(NSCLC) 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.

목차

제1장 조사 목적과 전제조건

• 조사 목적
• 전제조건
• 약어

제2장 시장 전망

• 보고서 설명
  • 시장 정의와 범위
• 주요 요약
• Coherent Opportunity Map (COM)

제3장 시장 역학, 규제, 동향 분석

• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
• 영향 분석
• 시장 동향
• 규제 시나리오
• 인수와 제휴 시나리오
• 자금조달과 투자
• PEST 분석
• Porter의 Five Forces 분석

제4장 세계의 비소세포폐암(NSCLC) 시장 - 코로나바이러스(COVID-19) 팬데믹의 영향

• 전체적인 영향
• 정부 이니셔티브
• 시장에 대한 COVID-19의 영향

제5장 세계의 비소세포폐암(NSCLC) 시장, 유형별, 2020-2032년(10억 달러)

• 서론
• 선암
• 편평상피암
• 대세포 암종
• 대세포 신경내분비종양

제6장 세계의 비소세포폐암(NSCLC) 시장, 치료별, 2020-2032년(10억 달러)

• 서론
• 화학요법
• 표적치료
• Bevacizumab (Avastin)
• Necitumumab (Portrazza)
• Ramucirumab (Cyramza)
• 면역치료
• Nivolumab (Opdivo)
• Atezolizumab (Tecentriq)
• 기타

제7장 세계의 비소세포폐암(NSCLC) 시장, 최종사용자별, 2020-2032년(10억 달러)

• 서론
• 병원
• 재택치료
• 전문 클리닉
• 기타

제8장 세계의 비소세포폐암(NSCLC) 시장, 지역별, 2020-2032년(10억 달러)

• 서론
• 북미
• 라틴아메리카
• 유럽
• 아시아태평양
• 중동
• 아프리카

제9장 경쟁 구도

• 기업 개요
  • F. Hoffmann-La Roche Ltd
  • Honeywell International Inc.
  • AstraZeneca PLC
  • Merck &Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG

제10장 애널리스트 추천 사항

• 융성과 쇠퇴
• Coherent Opportunity Map

제11장 섹션

• 참고 문헌
• 조사 방법

영문목차

Global Non-Small Cell Lung Cancer Market is estimated to be valued at USD 28.61 Bn in 2025 and is expected to reach USD 54.38 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.6% from 2025 to 2032.

Figure. Non-Small Cell Lung Cancer Market Share (%), By Region 2025

Non-small cell lung cancer (NSCLC) is the most prevalent type of lung cancer that accounts for around 85% of all lung cancers. It is among the leading causes of cancer-related deaths worldwide. Global non-small cell lung cancer market growth is driven by factors like rising prevalence of smoking habits and environmental pollution, increasing research & development activities for advanced treatment options and growing demand for targeted and personalized medicines. However, high treatment costs hampers the market growth.

Market Dynamics:

Global non-small cell lung cancer market growth is driven by increasing prevalence of smoking across both developed and developing nations, growing environmental pollution levels and aging population. According to WHO, around 1.80 million new lung cancer cases are reported globally each year, majority of which are NSCLC. Advancements in targeted therapies and cancer treatment modalities offers opportunities for market players. However, high costs associated with targeted drugs and lack of awareness in low-income countries hampers the market growth. Moreover, risk of drug failure during trials also negatively impacts R&D activities.

Key features of the study:

• This report provides in-depth analysis of the global non-small cell lung cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global non-small cell lung cancer market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include AstraZeneca, Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Celgene Corporation, Merck KGaA, Johnson & Johnson.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global non-small cell lung cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global non-small cell lung cancer market.

Detailed Segmentation-

• By Type
  • Adenocarcinoma
  • Squamous Cell Carcinoma
  • Large Cell Carcinoma
  • Large Cell Neuroendocrine Tumors
• Treatment
  • Chemotherapy
  • Targeted Therapy
  • Bevacizumab
  • Necitumumab
  • Ramucirumab
  • Immunotherapy
  • Nivolumab
  • Atezolizumab
  • Others
• End User
  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Hoffmann-La Roche Ltd
  • Honeywell International Inc.
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Teva Pharmaceutical

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Type
  • Market Snapshot, By Treatment
  • Market Snapshot, By End User
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Acquisitions and Partnerships Scenario
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Non-Small Cell Lung Cancer Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Non-Small Cell Lung Cancer Market, By Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Adenocarcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Squamous Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Large Cell Carcinoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Large Cell Neuroendocrine Tumors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Non-Small Cell Lung Cancer Market, By Treatment, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Chemotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Targeted Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bevacizumab (Avastin)
• Necitumumab (Portrazza)
• Ramucirumab (Cyramza)
• Immunotherapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Nivolumab (Opdivo)
• Atezolizumab (Tecentriq)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Non-Small Cell Lung Cancer Market, By End User, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospitals
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home Care
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Specialty Clinics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Non-Small Cell Lung Cancer Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • F. Hoffmann-La Roche Ltd
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Honeywell International Inc.
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • AstraZeneca PLC
    • Company Highlights
    • Method Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Boehringer Ingelheim International GmbH
  • Celgene Corporation
  • Amgen Inc.
  • Johnson & Johnson
  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. Section

• References
• Research Methodology
• About Us and Sales Contact

"